X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
IVS-3001 is Invectys’ cutting-edge CAR-T cell therapy, targeting the rarely exploited immune checkpoint and tumor specific antigen known as HLA-G, which is investigated for the treatment of Renal Cell Carcinoma.
Lead Product(s): IVS-3001,Fludarabine Phosphate,Cyclophosphamide
Therapeutic Area: Oncology Product Name: IVS-3001
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 31, 2023
Details:
IVS-3001 is Invectys’ cutting-edge CAR-T cell therapy, targeting the rarely exploited immune checkpoint and tumor specific antigen known as HLA-G, which is investigated for the treatment of Solid Tumors.
Lead Product(s): IVS-3001,Fludarabine Phosphate,Cyclophosphamide
Therapeutic Area: Oncology Product Name: IVS-3001
Highest Development Status: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: M.D. Anderson Cancer Center
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 13, 2023
Details:
IVS-3001, Invectys’s lead engineered human leukocyte antigen A (HLA-G) targeting chimeric antigen receptor (CAR) T cell therapy for the treatment of solid tumors.
Lead Product(s): HLA-G/CAR-T Cell Therapy
Therapeutic Area: Oncology Product Name: IVS-3001
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: CTMC
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 20, 2022
Details:
IVS-3001 is an HLA-G-targeting chimeric antigen receptor (CAR) T cell therapy. HLA-G is not only an immune checkpoint but also a tumor-specific antigen. IVS-3001 preclinical studies have generated adequate data to support efficacy and safety of the CAR-T therapy.
Lead Product(s): HLA-G/CAR-T Cell Therapy
Therapeutic Area: Oncology Product Name: IVS-3001
Highest Development Status: IND EnablingProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: CTMA
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 19, 2022
Details:
The collaboration will build upon the HLA-G platform pioneered by Invectys to advance novel CAR T cell therapies including lead asset IVS-3001, through preclinical development with CTMC into early-phase clinical studies at MD Anderson.
Lead Product(s): HLA-G/CAR-T Cell Therapy
Therapeutic Area: Oncology Product Name: IVS-3001
Highest Development Status: PreclinicalProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: The University of Texas MD Anderson Cancer Center
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration June 16, 2022
Details:
This is the first in-human study of INVAC-1, an immune-therapeutic DNA vaccine for the treatment of cancer.
Lead Product(s): INVAC-1
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 08, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
